MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Harmony Biosciences Holdings Inc

Fermé

SecteurSoins de santé

35.57 -6.96

Résumé

Variation du prix de l'action

24h

Actuel

Min

34.58

Max

38.22

Chiffres clés

By Trading Economics

Revenu

11M

51M

Ventes

39M

239M

P/E

Moyenne du Secteur

12.073

87.826

BPA

1.08

Marge bénéficiaire

21.242

Employés

268

EBITDA

14M

73M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+15.74% upside

Dividendes

By Dow Jones

Prochains Résultats

24 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

517M

2.2B

Ouverture précédente

42.53

Clôture précédente

35.57

Sentiment de l'Actualité

By Acuity

35%

65%

120 / 361 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 janv. 2026, 19:05 UTC

Principaux Mouvements du Marché

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 janv. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 janv. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 janv. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 janv. 2026, 23:13 UTC

Acquisitions, Fusions, Rachats

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 janv. 2026, 23:10 UTC

Acquisitions, Fusions, Rachats

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 janv. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 janv. 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

13 janv. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 janv. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 janv. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 janv. 2026, 21:15 UTC

Acquisitions, Fusions, Rachats

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 janv. 2026, 21:08 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 janv. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 janv. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 janv. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 janv. 2026, 19:08 UTC

Acquisitions, Fusions, Rachats

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 janv. 2026, 19:03 UTC

Résultats

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 janv. 2026, 18:50 UTC

Résultats

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 janv. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 janv. 2026, 17:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

13 janv. 2026, 17:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 janv. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 janv. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 janv. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 janv. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 janv. 2026, 17:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

13 janv. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 janv. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Comparaison

Variation de prix

Harmony Biosciences Holdings Inc prévision

Objectif de Prix

By TipRanks

15.74% hausse

Prévisions sur 12 Mois

Moyen 43.83 USD  15.74%

Haut 55 USD

Bas 32 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

5

Achat

0

Maintien

1

Vente

Score Technique

By Trading Central

29.8 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Very Strong Bearish Evidence

Sentiment

By Acuity

120 / 361Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat